Vaccine Adjuvants Market Size

Vaccine Adjuvants Market Size

The global vaccine adjuvants market size was valued at around USD 1.3 billion in 2024 and is estimated to grow at 6.5% CAGR from 2025 to 2034. Vaccine adjuvants are substances added to vaccines to enhance the body's immune response to the antigen. They improve vaccine efficacy by stimulating the immune system, ensuring a stronger and longer-lasting immune response. Adjuvants can reduce the amount of antigen needed in a vaccine, making it more cost-effective and efficient.

To get key market trends

  Download Free Sample

The rising incidence of cervical cancer and infectious diseases such as human papillomavirus (HPV), HIV, tuberculosis, and other severe illnesses is anticipated to significantly drive the demand for vaccine adjuvants. According to the American Cancer Society, cervical cancer ranks as the fourth most common cancer among women worldwide, with an estimated 13,820 new cases and 4,360 deaths projected in 2024. This alarming incidence rate underscores the urgent need for effective vaccines and adjuvants to combat these diseases.
 

In addition, the increasing emphasis on achieving long-lasting immunity against both existing and emerging diseases is likely to further boost the demand for adjuvants. The Centers for Disease Control and Prevention (CDC) indicates that adjuvants are incorporated into certain vaccines to enhance the immune response, allowing for a reduction in the amount of antigen needed or the number of doses required. This efficiency could lead to a higher adoption rate of adjuvanted vaccines.